The aim of this study was to assess protein overexpression and gene copy number alterations of MET in @entity43 , and to assess its potential as a novel therapeutic target. Ninety cases of clear-cell @entity420 were analyzed for MET protein overexpression and copy number alterations of the MET gene by immunohistochemistry and brightfield double in situ hybridization, respectively. In addition, 101 cases of the @entity43 at advanced stages were also evaluated for comparison. MET overexpression was assigned when complete membrane staining with moderate or strong intensity was observed in at least 10% of the @entity5 cells examined. Double in situ hybridization was determined as positive when the @entity5 exhibited high-level polysomy (>= 4 copies in >= 40% of @entity5 cells) or @entity74 . MET overexpression was detected in 20 of 90 clear-cell @entity420 (22%) and none of 111 @entity43 . Double in situ hybridization was positive in 21 of 89 informative clear-cell @entity420 (24%) and only 3 @entity43 (3%). In the whole population, true amplification of the MET gene was detected only in the clear-cell @entity420 histology (five cases, 6%). In clear-cell @entity420 , double in situ hybridization positivity was highly correlated with the presence of MET overexpression and a poorly differentiated histology of @entity5 (P=0.0105 and 0.00038, respectively). For the @entity1 with clear-cell @entity420 , MET overexpression, as well as advanced clinical stage and the poorly differentiated histology of @entity5 , was identified as an independent unfavorable prognostic factor for overall survival. In conclusion, among @entity43 , the amplification of the MET proto-oncogene is highly selective and commonly occurs in clear-cell @entity420 . MET could serve as a biomarker for the prognostication of @entity1 with clear-cell @entity420 and @entity5 progression, and has potential as a novel therapeutic target for this @entity189 .

Gene amplification and protein overexpression of MET are common events in XXXX : their roles in @entity5 progression and prognostication of the @entity1 .

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinomas', 'ovarian clear-cell adenocarcinoma', 'non-clear-cell type ovarian carcinomas'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity74 :: ('MESH:D030342', 'Disease') :: ['MET gene amplification'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian clear-cell adenocarcinoma']
